Clinical Trial Update: Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing KW-0761 (mogamulizumab) to vorinostat in relapsed/refractory cutaneous T-cell lymphoma has completed and results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Poteligeo (mogamulizumab)
• Zolinza (vorinostat)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Cutaneous T-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2019-04-11